Dr. Lihui Wang obtained her quantification in Medicine in Peking University, China and her PhD degree in the University of Liverpool. She has been active in research on a variety of haematological malignancies in China, France, Scotland and England. Dr. Wang has been a Senior Clinical Scientist in Department of Haematology, Royal Liverpool University Hospital since year 2000. She has integrated both research project and NHS service to improve the molecular diagnosis, prognosis and monitoring for patients with haematological malignancies. Her research was mainly in investigating the role of BCR-ABL1 gene transcript monitoring in CML (Chronic Myeloid Leukaemia) patients under various clinical settings, the mechanism of tyrosine kinase inhibitor resistance in CML and the molecular mechanism of CML blast crisis (BC) transformation.
Dr. Wang has been involved in establishing and standardising BCR-ABL1 gene transcript monitoring in Liverpool, UK and across the world (WHO standard). Her role in NHS service was to establish and supervise molecular diagnostic and molecular monitoring service for patients with chronic myeloid leukaemia (CML), acute leukaemia and myeloproliferative neoplasms (MPN). Since 2018, Dr. Wang has been the Lead Scientist for Molecular Diagnostics, Haemato-oncology Diagnostic Service (HODS) in Royal Liverpool University Hospital. Her role was to establish and supervise the Haemato-oncology molecular diagnostic service for the region of Merseyside and Cheshire. Since 2019, Dr. Wang has been the Lead Scientist for NHS England Northwest Liverpool LCL Genomic Laboratory Hub (GLH).